<DOC>
	<DOCNO>NCT00073463</DOCNO>
	<brief_summary>The purpose study confirm improvement pulmonary function cytokine level observe recently complete multidose aerosol study treatment Cystic Fibrosis ( CF ) .</brief_summary>
	<brief_title>Safety Efficacy Recombinant Adeno-Associated Virus Containing CFTR Gene Treatment Cystic Fibrosis</brief_title>
	<detailed_description>Cystic Fibrosis autosomal recessive disorder incidence approximately 1 33000 live birth . It due defect CFTR gene , locate chromosome 7 . Gene Therapy hold promise addressing primary defect CF reconstitute CFTR function lung . tgAAVCF , genetically engineer contain CFTR gene , extremely well tolerate follow single multiple dose administration nose , sinus , lung . Dose-dependent gene transfer demonstrate . Although vector gene expression detect , evidence consistent biological activity observe maxillary sinus study , statistically significant change FEV1 IL-8 level observe recently complete multidose aerosol study . These finding worthy investigation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Eligible subject randomize two aerosolized dos either tgAAVCF placebo 30 day apart . Subjects undergo pulmonary function test every two week active portion study ( three month ) follow safety total seven month .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Gene Transfer</keyword>
	<keyword>Pulmonary function</keyword>
</DOC>